Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Analyst sentiment is mixed: Sarepta Therapeutics has a consensus “Hold” rating from 20 firms, with six sells, five holds and nine buys. The average 12-month price target is $25.69, above the reported opening price of $20.67.
• Recent quarterly results beat estimates: Sarepta reported adjusted EPS of $0.64 versus the $0.22 consensus and revenue of $401.25 million versus expectations of $366.39 million. However, revenue declined 34.3% year over year and the company posted a negative net margin.
• Institutional ownership remains high: Institutional investors own 86.68% of Sarepta’s shares, while several funds recently initiated or increased positions in the biotechnology company.

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have received a consensus rating of "Hold" from the twenty ratings firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $25.6875.

Several equities analysts have recently issued reports on SRPT shares. Wolfe Research upgraded Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, July 9th. HC Wainwright reiterated a "buy" rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Benchmark reissued a "sell" rating on shares of Sarepta Therapeutics in a report on Wednesday, September 9th. Wall Street Zen downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings upgraded shares of Sarepta Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, September 8th.

Sarepta Therapeutics Trading Up 4.6%

SRPT opened at $20.67 on Friday. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -7.13, a P/E/G ratio of 0.28 and a beta of 0.27. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a twelve month low of $14.68 and a twelve month high of $25.32. The company has a 50-day simple moving average of $18.60 and a 200 day simple moving average of $18.65.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. During the same quarter last year, the business posted $2.02 EPS. The firm's revenue for the quarter was down 34.3% on a year-over-year basis. Analysts predict that Sarepta Therapeutics will post 3.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. acquired a new position in shares of Sarepta Therapeutics in the second quarter worth approximately $27,000. Larson Financial Group LLC lifted its position in shares of Sarepta Therapeutics by 82.5% in the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 851 shares during the period. Nykredit A S bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at $43,000. Ancora Advisors LLC bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at $45,000. Finally, Hantz Financial Services Inc. increased its position in shares of Sarepta Therapeutics by 348.3% during the fourth quarter. Hantz Financial Services Inc. now owns 2,784 shares of the biotechnology company's stock worth $60,000 after buying an additional 2,163 shares during the period. Institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. Its research platforms include RNA-based technologies, gene therapy and gene-editing approaches designed to address the underlying causes of genetic disorders.

The company's primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for eligible patients with specific genetic mutations, as well as Elevidys, a gene therapy developed to treat certain patients with DMD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.